NASDAQ:ABCM - Abcam Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.00
  • Forecasted Upside: 16.09 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.95
▲ +0.18 (0.96%)

This chart shows the closing price for ABCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abcam Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCM

Analyst Price Target is $22.00
▲ +16.09% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Abcam in the last 3 months. The average price target is $22.00, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 16.09% upside from the last price of $18.95.

This chart shows the closing price for ABCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Abcam. This rating has held steady since February 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/12/2021Berenberg BankReiterated RatingHoldLow
3/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
3/9/2021Royal Bank of CanadaReiterated RatingOutperformLow
3/9/2021SVB LeerinkLower Price TargetOutperform$26.00 ➝ $25.00Low
1/28/2021Morgan StanleyInitiated CoverageHold$21.00Low
1/27/2021SVB LeerinkBoost Price TargetOutperform$22.00 ➝ $26.00Low
1/12/2021Royal Bank of CanadaUpgradeSector Perform ➝ OutperformHigh
11/16/2020William BlairInitiated CoverageOutperformLow
11/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
11/16/2020SVB LeerinkInitiated CoverageOutperform$22.00Low
11/16/2020Morgan StanleyInitiated CoverageEqual Weight$21.00Low
11/9/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformMedium
(Data available from 6/21/2016 forward)
Abcam logo
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $18.95
Low: $18.68
High: $19.04

50 Day Range

MA: $20.09
Low: $18.47
High: $22.11

52 Week Range

Now: $18.95
Low: $17.71
High: $24.69

Volume

125,482 shs

Average Volume

187,608 shs

Market Capitalization

$4.30 billion

P/E Ratio

90.24

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abcam?

The following Wall Street sell-side analysts have issued stock ratings on Abcam in the last year: Bank of America Co., Berenberg Bank, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ABCM.

What is the current price target for Abcam?

3 Wall Street analysts have set twelve-month price targets for Abcam in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 16.1%. SVB Leerink LLC has the highest price target set, predicting ABCM will reach $25.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $20.00 for Abcam in the next year.
View the latest price targets for ABCM.

What is the current consensus analyst rating for Abcam?

Abcam currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABCM, but not buy more shares or sell existing shares.
View the latest ratings for ABCM.

What other companies compete with Abcam?

How do I contact Abcam's investor relations team?

The company's listed phone number is 44 1223 696 000 and its investor relations email address is [email protected] The official website for Abcam is www.abcam.com.